Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210 Meeting Abstract
| Authors: | Balar, A. V.; Dreicer, R.; Loriot, Y.; Perez-Gracia, J. L.; Hoffman-Censits, J. H.; Petrylak, D. P.; Van Der Heijden, M. S.; Ding, B.; Shen, X.; Rosenberg, J. E. |
| Abstract Title: | Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210 |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| End Page: | 246s |
| Language: | English |
| ACCESSION: | WOS:000442916002050 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4523 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4523 -- Source: Wos |
